New Treatment Option Moving Towards Reimbursement for Adults with Operable Early-Stage NSCLC

New Treatment Option Moving Towards Reimbursement for Adults with Operable Early-Stage NSCLC

Pembrolizumab (Keytruda) is one step closer to being funded via Canada’s various provincial drug plans for the treatment of adults with operable stage II, IIIA, or IIIB (T3 to 4N2) non-small cell lung cancer (NSCLC) to be used with chemotherapy before surgery to shrink the cancer and then used on its own after surgery to help keep the cancer from coming back, if certain conditions are met.

A Landmark Win, But More Work to Be Done 

Two little girls holding canadian flags

Everyone Deserves to Breathe Easy. We need to speak up so Canadians across the country can get the help they need close to home. Thanks to relentless advocacy, we acknowledged a landmark $32.5 billion settlement against tobacco companies — an important step in acknowledging decades of harm. But now, the real work begins.

Lung health has never been more urgent. Would you consider a gift that will help us protect it?

Lung Health Foundation Applauds U.K.’s Bold Step to Ban Tobacco Products to Those Born in 2009 or Later – and Asks Canadians to “Take the Pledge to Create a Smoke-Free Generation”

In a resounding victory for lung health, U.K. lawmakers have set a groundbreaking precedent by banning tobacco product sales to individuals born in 2009 or later. This monumental move has ignited a flame of hope for a future where our children breathe easier and live longer, free from the chains of smoking-related illnesses. The Lung Health Foundation celebrates this pivotal moment and urges Canadians to heed the call for change. It’s not just about imposing taxes or erecting barriers; it’s about fostering a grassroots movement that champions the well-being of our youth.